Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. (Q34647844)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

ChEBI release 2020-05-28

ChEBI ID

73274

canagliflozin hemihydrate

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Denise M Kolanczyk

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alison M Walton

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

311-319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

Diagnosis and classification of diabetes mellitus

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Combining sulfonylureas and other oral agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Renal Na(+)-glucose cotransporters

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Glucose control by the kidney: an emerging target in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Role of metformin for weight management in patients without type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

Dapagliflozin for the treatment of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110514

31 March 2020

Identifiers

DOI

10.2146/AJHP110514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370138%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference